This investigator-initiated, all-comers prospective trial is registered with www.clinicaltrials.gov, registration number NCT03428048. The study was approved by the Institutional Review Board (IRB) of ADVARRA IRB, Columbia, MD. USA (Pro00026648) and all interventions were performed in accordance with relevant guidelines and regulations as they specify protection of human subjects’ participation in outcomes research. Informed consent for research was obtained from all subjects prior to enrollment. The primary endpoint is the 6-month change (from baseline which was pre-procedure), in the Atrial Fibrillation Effect on QualiTy-of Life (AFEQT) Questionnaire overall score. The AFEQT is recognized as a validated assessment to clinically follow patients with AF 8. Secondary endpoints include the 1-year change in AFEQT overall score, the duration of maintaining normal sinus rhythm (NSR), adverse events, and mortality. Maintaining NSR was defined as the length of time (days) until the first recurrence of atrial tachyarrhythmia after reaching 91 days. In alignment with the 2017 expert consensus statement on AF ablations, reoccurrences of atrial tachyarrhythmia during the first 90 days after the index procedure (blanking period) were not counted in the determination of failure of NSR5. The time of maintaining NSR was analyzed using non-parametric Kaplan-Meier survival analysis methods. An adverse event was tracked if it warranted an intervention or resulted in a prolonged length of stay.
Data Source
The data was collected prospectively and recorded and stored in a Microsoft Excel workbook. Variables collected included the demographics of age, sex, and race, as well as CHA2DS2-VAS-c, procedural complications and displayed in Table 1. Patient Characteristics.
Table 1
Patient Baseline Characteristics
Variable | | | Paroxysmal Diagnosis (N = 36) | | Persistent Diagnosis (N = 18) | | Total (N = 54) | | P-Value |
Sex | | | | | | | | | 0.42 |
Male | N (%) | | 22 (61) | | 13 (72) | | 35 (65) | | |
Female | | | 14 (39) | | 5 (28) | | 19 (35) | | |
Age at Enrollment | | | | | | | | | 0.74 |
Years | Mean (SD) | | 65.0 (9.4) | | 65.9 (9.6) | | 65.3 (9.4) | | |
| (Min, Max) | | (41, 84) | | (47, 80) | | (41, 84) | | |
CHA2DS2-VASc Score | | | | | | | | | 0.49 |
0 | N (%) | | 5 (14) | | 3 (17) | | 8 (15) | | |
1 | | | 8 (22) | | 2 (11) | | 10 (19) | | |
2 | | | 9 (25) | | 6 (33) | | 15 (28) | | |
3 | | | 6 (17) | | 5 (28) | | 11 (20) | | |
4 | | | 2 (6) | | 2 (11) | | 4 (7) | | |
5 | | | 5 (14) | | 0 (0) | | 5 (9) | | |
6 | | | 1 (3) | | 0 (0) | | 1 (2) | | |
Initial Ablation Procedure | | | | | | | | | < 0.001 |
Cryo | N (%) | | 29 (81) | | 2 (11) | | 31 (57) | | |
Hybrid | | | 1 (3) | | 2 (11) | | 3 (6) | | |
Hybrid/Clip | | | 0 (0) | | 7 (39) | | 7 (13) | | |
Laser | | | 2 (6) | | 0 (0) | | 2 (4) | | |
Maze | | | 0 (0) | | 3 (17) | | 3 (6) | | |
Maze/Clip | | | 3 (8) | | 4 (22) | | 7 (13) | | |
Unknown | | | 1 (3) | | 0 (0) | | 1 (2) | | |
Study Population
From 2017, all patients admitted (no exclusions) for epicardial and endocardial ablation of AF were asked to participate in our outcomes research study, The NEXUS Registry. The patients will be followed for up to ten years after the initial ablation with visits at 6 months and 1-year post-operation and annually thereafter. Patients participate in a shared- decision making process and were asked about their symptoms and function as it relates to AF prior to any ablation procedure.
Post ablation, rhythm status and charts were abstracted to determine if patients required direct current cardioversions (DCCVs) or had an ECG demonstrating AF episodes. Our institution is defined as rural and annually performs < 50 epicardial and endocardial ablations.
Ablation Procedures
Most of the patients (57%) received cryoablation followed by the hybrid procedure – a combination of endocardial and epicardial ablation (18%). Ten patients received epicardial ablation – the Modified MAZE (18%) and two patients received laser ablation (3%). The ablation strategy for endocardial ablation is pulmonary vein isolation and was facilitated by one electrophysiologist. Patients that experienced epicardial or surgical ablation (Maze-modified, Hybrid) were under the care of two cardiothoracic surgeons and classified as minimally invasive (non- sternotomy). All patients received general anesthesia, no surgical ablations were preformed concomitantly and hybrid is further defined as endo and epicardial ablation occurring within the same in-patient episode or within three months from the index procedure. Left atrial occlusion is managed with a surgical clip and delineated as such.
Statistical Analysis
Subject characteristics of age, sex, CHA2DS2 –VASc score, initial ablation procedure type and serious adverse events through hospitalization were summarized using descriptive statistics, with results presented both overall and by diagnosis type (paroxysmal vs persistent) and shown in Table 1. Continuous numeric variables are summarized using means and extreme values (minimum and maximum), and categorical variables are summarized using frequency counts and percentages. The 6-month and 1-year changes in the overall AFEQT score as well as the 4 subscale scores were tested using a 2-sided paired t-test on the scores at baseline and follow-up (6 months and 1 year), controlling the type 1 error rate at 0.05. The mean change along with the associated 95% confidence intervals (CI) and p-values are presented in Table 2. Outcomes for both the 6-month and 1-year changes along with the baseline mean and standard deviation (SD). The p-values are from the hypothesis test that the scores did not change from baseline. The duration of maintaining NSR was analyzed using a Kaplan-Meier survival analysis and displayed in Fig. 1. Normal Sinus Rhythm Duration Post AF Ablation. All analyses were conducted using SAS software, version 9.4 (SAS Institute, Cary, NC, USA).
Table 2
| | Baseline | | 6-Month Change | | 1-Year Change |
Outcome | | Mean (SD) | | N | Mean | 95% CI | P-Value | | N | Mean | 95% CI | P-Value |
Overall AFEQT | | 59 (25) | | 15 | 30 | (16, 43) | < 0.001 | | 19 | 22 | (14, 30) | < 0.001 |
Symptoms Subscale | | 64 (28) | | 15 | 28 | (14, 41) | < 0.001 | | 19 | 19 | (8, 30) | 0.002 |
Daily Activities Subscale | | 58 (31) | | 15 | 28 | (10, 46) | 0.005 | | 19 | 20 | (11, 29) | < 0.001 |
Treatment Concerns Subscale | | 56 (23) | | 15 | 33 | (19, 46) | < 0.001 | | 19 | 27 | (18, 37) | < 0.001 |
Treatment Satisfaction Subscale | | 48 (29) | | 15 | 48 | (29, 68) | < 0.001 | | 19 | 37 | (19, 54) | < 0.001 |